Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

Transthyretin Amyloidosis Treatment Market explores key drug advances, regulatory developments, and growth trends through 2035 ...

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

“The HELIOS-B study continues to deliver a robust data package showcasing the unique, differentiated value of vutrisiran as a first-line treatment option that can enable patients with ATTR-CM to ...

TOKYO - The Japanese Ministry of Health, Labour and Welfare has granted approval to BridgeBio Pharma, Inc.’s acoramidis, marketed under the brand name Beyonttra, for the treatment of adults with ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ...

Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative ...

Japan approved BridgeBio’s acoramidis (Beyonttra) for ATTR-CM, with AstraZeneca’s Alexion handling commercialization. BridgeBio will receive a $30 million milestone payment and low double ...

1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all ...